Vaccine-induced immune thrombosis and thrombocytopenia (VITT) is a new syndrome, which has emerged after introduction of the adenovirus vector-based COVID-19 vaccines ChAdOx1 nCoV-19 og Ad26.COV2-SVITT is characterised by venous thrombosis at unusual, and often multiple localisations, especially including cerebral venous sinus thrombosis. Besides, bleeding manifestations often occur. Biochemically, VITT is characterised by thrombocytopaenia and elevated fibrin d-dimer. VITT is a rapidly progressing and potentially life-threatening syndrome where rapid diagnosis and treatment are essential as argued in this review.
Download full-text PDF |
Source |
---|
Euro Surveill
January 2025
RKI-SOEP-2 Study Group is acknowledged at the end of the article.
BackgroundThe first Corona Monitoring Nationwide (RKI-SOEP) study (October 2020-February 2021) found a low pre-vaccine SARS-CoV-2 antibody seroprevalence (2.1%) in the German adult population (≥ 18 years).AimThe objective of this second RKI-SOEP (RKI-SOEP-2) study in November 2021-March 2022 was to estimate the prevalence of SARS-CoV-2-specific anti-spike and/or anti-nucleocapsid (anti-N) IgG antibodies (combined seroprevalence), past infection based on infection-induced seroprevalence (anti-N), and basic immunisation (at least two antigen contacts through vaccination or infection) in individuals aged ≥ 14 years.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
International University Semen Indonesia, Gresik, East Java, Indonesia.
Background: Recent evidence suggests a potential link between systemic inflammation induced by viral infections like COVID-19 and the exacerbation of neurodegenerative processes in Alzheimer's disease (AD). This study aims to explore the novel idea that COVID-19 vaccines may offer neuroprotective effects against the progression of AD, leveraging machine learning techniques to analyze multimodal data sets.
Method: We conducted a retrospective cohort study involving 10,000 participants aged 65 and older, with an initial diagnosis of early-stage AD, from five distinct geographic locations.
Background: The key advantage of active immunization is the induction of sustained, polyclonal antibody responses that are readily boosted by occasional immunizations. Recent clinical trial outcomes for monoclonal antibodies lecanemab and donanemab, establish the relevance of targeting pathological Abeta for clearing amyloid plaques in Alzheimer's disease. ACI-24.
View Article and Find Full Text PDFCardiol J
January 2025
Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Iran.
Background: To investigate whether the antiPCSK9 vaccine can affect the CRP and oxidative stress (OS) during acute systemic inflammation.
Methods: Male albino mice were randomly divided into three groups: non-treated mice (the sham group), treated with a nonspecific stimulator of the immune response - Freund's complete adjuvant (CFA; the CFA group), and vaccinated mice treated with CFA (the vaccine group). The vaccine group was subcutaneously immunized with the antiPCSK9 formulation, 4 × in bi-weekly intervals.
Curr Cardiol Rep
January 2025
Medical College, Hunan University of Chinese Medicine, Changsha, 410208, Hunan, China.
Purpose Of Review: This review aims to assess the current landscape of animal models used in myocarditis research, with a focus on understanding their utility in uncovering the pathophysiology of the disease. The goal is to evaluate these models' strengths and weaknesses and propose optimizations to make them more relevant and reliable for both mechanistic studies and therapeutic interventions in myocarditis.
Recent Findings: Recent studies have primarily utilized animal models, particularly viral and autoimmune myocarditis models, to study disease mechanisms.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!